



Patient metric data collection form for **RECENT ONSET** rheumatoid arthritis (RA)

Please use the correct form. There are separate forms for
RECENT ONSET and **ESTABLISHED** patients

This data collection form is for use *only* in RA patients
with **RECENT ONSET** disease
(i.e. patients ≤ 2 years from diagnosis)

Please review and complete every question

PLEASE COMPLETE ALL SECTIONS

UNIT AND PATIENT DETAILS				
	Unit (name).....			
Q1	Age (circle applicable) <30 years 30–40 years 41–50 years 51–60 years 61–70 years >70 years			
	Gender (circle applicable) Male Female			
REFERRAL FOR SPECIALIST TREATMENT				
Q2	Criteria	Date	Not known	
2.1	Date of referral		<input type="checkbox"/>	
2.2	First date with specialist		<input type="checkbox"/>	
		Yes	No	Not known
2.3	Was time from referral to first treatment ≤ 6 weeks?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2.4	Was the patient diagnosed with RA/inflammatory polyarthritis?	<input type="checkbox"/>	<input type="checkbox"/>	
		Date	Not known	
2.5	Date diagnosis first made		<input type="checkbox"/>	
DISEASE ACTIVITY ASSESSMENT				
Q3	Criteria	Yes	No	Not clinically relevant
3.1	Does the patient have DAS28 $>2.6^1$?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
If you answered 'No' to question 3.1, please go to question 4 on the next page				
3.2	Has the patient been seen every 4–6 weeks?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
If 'No', please indicate why (circle applicable): Clinic capacity Did not attend Other				
	Criteria	Yes	No	Not clinically relevant
3.3	Was DAS28 assessed at every visit?			

PLEASE COMPLETE ALL SECTIONS

TREATMENT MODIFICATION					
Q4	Criteria	Yes		No	
4.1	Has the patient received rapid escalation of treatment in line with NICE guidance ² ?	<input type="checkbox"/>		<input type="checkbox"/>	
4.2	Has the patient achieved clinical remission or DAS28 ≤ 2.6 ¹ ?	<input type="checkbox"/>		<input type="checkbox"/>	
4.3	Is the patient on biologics?	<input type="checkbox"/>		<input type="checkbox"/>	
<i>If you answered 'No' to question 4.3, please go to question 5 on the next page</i>					
		Yes		No	
				Patient on biologics for <6 months	
4.4	Has the patient achieved an adequate response within the first 6 months of initiating therapy (an improvement in DAS28 of 1.2 points or more) in line with NICE guidance ² ?	<input type="checkbox"/>		<input type="checkbox"/>	
<i>If you answered 'Yes' or 'Patient on biologics for <6 months' to question 4.4, please go to question 5 on the next page</i>					
		Yes	No	Patient on biologics for <6 months	Active clinical decision not to do so
4.5	If the patient has <u>NOT</u> achieved a timely improvement in DAS28 of 1.2 points or more, has the patient been moved to the next treatment in the pathway according to NICE guidance ^{3,4} ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

PLEASE COMPLETE ALL SECTIONS

ANNUAL REVIEW [#]				
<i>Is it <u>CLEARLY DOCUMENTED</u> that the following actions have been carried out within the <u>LAST 12 MONTHS</u>:</i>				
Q5	Criteria	Yes	No	Patient <1 year from diagnosis
5.1	Damage has been assessed, and functional ability measured (using, for example, the Health Assessment Questionnaire [HAQ])?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.2	The patient has been checked for the development of comorbidities (e.g., hypertension, ischaemic heart disease, osteoporosis, depression)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.3	There was assessment of symptoms that suggest complications (e.g., vasculitis and disease of the cervical spine, lung, eyes)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.4	Appropriate cross referral within the multidisciplinary team was organised?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5.5	The patient has been asked about the impact of RA on their day-to-day experience of life (e.g. employment, social, sexual, functional activities of daily living)?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

[#]NICE recommend an ‘annual review’ with each RA patient (NICE clinical guideline 79 – Rheumatoid arthritis: section 1.5.1.4)

References

¹ Wells et al. Ann Rheum Dis 2009;68:954–960. In this paper DAS28 <2.6 is defined as the ‘threshold for remission’. ²NICE clinical guideline 79 – Rheumatoid arthritis. Available at: www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf (accessed August 2010).

³NICE technology appraisal guidance 195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. Available at: <http://guidance.nice.org.uk/TA195/Guidance/pdf/English> (accessed September 2010).

⁴NICE technology appraisal guidance 198: Tocilizumab for the treatment of rheumatoid arthritis. Available at: <http://guidance.nice.org.uk/TA198/Guidance/pdf/English> (accessed September 2010). Section 1.1.

If you have any queries please contact CQRA (email cqra@nras.org.uk)